Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director · CHIEF TECHNOLOGY OFFICER | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,821,870 |
Ending reported balance
After 2026-08-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 7,363 · Balance 4,804,051 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-08-18 · Tax withholding · Disposed 1,778 · Balance 4,802,273 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-08-18 · Exercise / conversion · Acquired 5,525 · Balance 4,807,798 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-08-18 · Tax withholding · Disposed 1,346 · Balance 4,806,452 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 6,162 · Balance 4,812,614 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-08-18 · Tax withholding · Disposed 1,501 · Balance 4,811,113 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-08-18 · Exercise / conversion · Acquired 14,220 · Balance 4,825,333 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-08-18 · Tax withholding · Disposed 3,463 · Balance 4,821,870 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,189 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 7,363 · Balance 17,189 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,995 |
Reported balance
After 2026-08-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-18 · Exercise / conversion · Disposed 5,525 · Balance 34,995 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 63,688 |
Reported balance
After 2026-08-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-18 · Exercise / conversion · Disposed 6,162 · Balance 63,688 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 203,835 |
Reported balance
After 2026-08-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-18 · Exercise / conversion · Disposed 14,220 · Balance 203,835 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.
F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2025 Filed Nov 21, 2025 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 483 | $5.53 | $2,670.99 |
DisclosureSEC source: 0001874041-25-000002 · form4-11212025_121157.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,058,917 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001874041-25-000002 · form4-11212025_121157.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,059,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · derivative · entry 12 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,337 Underlying: Common Stock · 6,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · derivative · entry 11 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,094 Underlying: Common Stock · 5,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · derivative · entry 10 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,640 Underlying: Common Stock · 7,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · derivative · entry 9 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,313 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,468 | $4.06 | $5,960.08 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 8 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,057,419 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 7 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,058,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,498 | $4.06 | $6,081.88 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,052,725 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,054,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,184 | $4.06 | $8,867.04 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,048,698 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,050,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $4.06 | $2,387.28 |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,043,519 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022524 · form4-08202025_090828.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,044,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · derivative · entry 12 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,499 Underlying: Common Stock · 4,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · derivative · entry 11 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,619 Underlying: Common Stock · 3,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · derivative · entry 10 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,003 Underlying: Common Stock · 4,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · derivative · entry 9 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,294 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,219 | $2.69 | $3,279.11 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 8 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042,126 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 7 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,043,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,093 | $2.69 | $2,940.17 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,039,237 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,456 | $2.69 | $3,916.64 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,036,647 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,038,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $2.69 | $1,581.72 |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,033,195 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013976 · form4-05212025_090505.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,033,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · derivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,302 Underlying: Common Stock · 7,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 9,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · derivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,911 Underlying: Common Stock · 9,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,185 | $4.36 | $9,526.60 |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,031,802 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,033,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,911 | $4.36 | $12,691.96 |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,026,621 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 9,817 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007888 · form4-03122025_090329.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,029,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 98,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007283 · form4-03062025_100342.xml · derivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,607 Underlying: Common Stock · 98,607 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 156,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-25-007283 · form4-03062025_100342.xml · derivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,250 Underlying: Common Stock · 156,250 shares Expires 2035-03-04 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:11 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004926 · form4-02202025_110227.xml · derivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,275 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:11 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $5.31 | $3,122.28 |
DisclosureSEC source: 0001415889-25-004926 · form4-02202025_110227.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,019,715 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:11 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004926 · form4-02202025_110227.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,020,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · derivative · entry 9 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,668 Underlying: Common Stock · 5,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · derivative · entry 8 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,728 Underlying: Common Stock · 7,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,256 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,346 | $6.03 | $8,116.38 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,018,322 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,019,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,793 | $6.03 | $10,811.79 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,014,143 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,015,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 483 | $6.03 | $2,912.49 |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,008,573 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027365 · form4-11202024_111112.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,009,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · derivative · entry 9 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,193 Underlying: Common Stock · 5,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · derivative · entry 8 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,091 Underlying: Common Stock · 7,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,237 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,346 | $5.53 | $7,443.38 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,007,075 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.